Big Pharma's Bad Attitude: Are CEOs Giving Industry A Bad Rep?
Big pharma has been big news recently, with politicians and the general public wading into industry debates on drug pricing, profit-making and trial transparency under the gleeful eye of the international press. Unsurprisingly, pharma has come out on the losing side of these debates, its scientific accomplishments forced into the shadows by the actions of executives such as Martin Shkreli, who have ensured that the spotlight is firmly on the people behind the businesses rather than the products they manufacture.
You may also be interested in...
Long before Valeant Pharmaceuticals International Inc. acquired North Carolina-based Salix Pharmaceuticals Ltd. in 2015, the latter firm was engaging in illegal kickback activities, for which its parent company is now left holding the bag in paying out $54m to settle the charges – another black eye for the Canadian firm's reputation.
The latest PatientView report on the corporate reputation of pharma from the perspective of patient groups has been published. In a survey of pharma's corporate reputation, ViiV Healthcare retained the overall top spot, with AbbVie a close second. Of the 48 companies that patient groups commented on, the bottom ranked companies were Valeant and Hospira.
GarmaMabs Pharma has appointed Martine J. George an independent board member.